168 related articles for article (PubMed ID: 37552407)
1. Telmisartan versus EnalapRil In heart failure with redUced ejection fraction patients with Moderately impaired kidney Functions; randomized controlled trial: "TRIUMF trial".
Samir A; Aboel-Naga S; Shehata A; Abdelhamid M
Egypt Heart J; 2023 Aug; 75(1):68. PubMed ID: 37552407
[TBL] [Abstract][Full Text] [Related]
2. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators.
Dunselman PH;
Int J Cardiol; 2001 Feb; 77(2-3):131-8; discussion 139-40. PubMed ID: 11182175
[TBL] [Abstract][Full Text] [Related]
3. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
McCallum W; Tighiouart H; Ku E; Salem D; Sarnak MJ
Am J Kidney Dis; 2020 Jan; 75(1):21-29. PubMed ID: 31303349
[TBL] [Abstract][Full Text] [Related]
4. Predictors and Prognostic Value of Worsening Renal Function During Admission in HFpEF Versus HFrEF: Data From the KorAHF (Korean Acute Heart Failure) Registry.
Kang J; Park JJ; Cho YJ; Oh IY; Park HA; Lee SE; Kim MS; Cho HJ; Lee HY; Choi JO; Hwang KK; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29535141
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril.
Smith DH
Clin Ther; 2002 Oct; 24(10):1484-501. PubMed ID: 12462282
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.
Beldhuis IE; Streng KW; Ter Maaten JM; Voors AA; van der Meer P; Rossignol P; McMurray JJ; Damman K
Circ Heart Fail; 2017 Feb; 10(2):. PubMed ID: 28209765
[TBL] [Abstract][Full Text] [Related]
7. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Desai AS; Solomon SD; Shah AM; Claggett BL; Fang JC; Izzo J; McCague K; Abbas CA; Rocha R; Mitchell GF;
JAMA; 2019 Sep; 322(11):1077-1084. PubMed ID: 31475296
[TBL] [Abstract][Full Text] [Related]
8. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
Damman K; Solomon SD; Pfeffer MA; Swedberg K; Yusuf S; Young JB; Rouleau JL; Granger CB; McMurray JJ
Eur J Heart Fail; 2016 Dec; 18(12):1508-1517. PubMed ID: 27427441
[TBL] [Abstract][Full Text] [Related]
9. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
Beldhuis IE; Lam CSP; Testani JM; Voors AA; Van Spall HGC; Ter Maaten JM; Damman K
Circulation; 2022 Mar; 145(9):693-712. PubMed ID: 35226558
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction - Results From the PARALLEL-HF Study.
Tsutsui H; Momomura SI; Saito Y; Ito H; Yamamoto K; Sakata Y; Desai AS; Ohishi T; Iimori T; Kitamura T; Guo W;
Circ J; 2021 Apr; 85(5):584-594. PubMed ID: 33731544
[TBL] [Abstract][Full Text] [Related]
11. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan versus enalapril on exercise capacity in patients with heart failure with reduced ejection fraction: A randomized, double-blind, active-controlled study.
Dos Santos MR; Alves MNN; Jordão CP; Pinto CEN; Correa KTS; de Souza FR; da Fonseca GWP; Tomaz Filho J; Costa M; Pereira RMR; Negrão CE; Barretto ACP
Am Heart J; 2021 Sep; 239():1-10. PubMed ID: 33992607
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists.
Ambrosy AP; Braunwald E; Morrow DA; DeVore AD; McCague K; Meng X; Duffy CI; Rocha R; Velazquez EJ;
J Am Coll Cardiol; 2020 Sep; 76(9):1034-1048. PubMed ID: 32854838
[TBL] [Abstract][Full Text] [Related]
15. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
16. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
Damman K; Perez AC; Anand IS; Komajda M; McKelvie RS; Zile MR; Massie B; Carson PE; McMurray JJ
J Am Coll Cardiol; 2014 Sep; 64(11):1106-13. PubMed ID: 25212644
[TBL] [Abstract][Full Text] [Related]
17. Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
Redouane B; Greene SJ; Fudim M; Vaduganathan M; Ambrosy AP; Sun JL; DeVore AD; McNulty SE; Mentz RJ; Hernandez AF; Felker GM; Cooper LB; Borlaug BA; Velazquez EJ; Margulies KB; Sharma A
Circ Heart Fail; 2020 May; 13(5):e006758. PubMed ID: 32362166
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Nedogoda SV; Ledyaeva AA; Chumachok EV; Tsoma VV; Mazina G; Salasyuk AS; Barykina IN
Clin Drug Investig; 2013 Aug; 33(8):553-61. PubMed ID: 23800977
[TBL] [Abstract][Full Text] [Related]
19. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Barnett A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
[TBL] [Abstract][Full Text] [Related]
20. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Nakamura T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H
Eur J Clin Invest; 2010 Sep; 40(9):790-6. PubMed ID: 20584070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
